Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

f-of-concept trial noted outlined above. With the positive initial results from that clinical trial and the decision to move forward to a Phase 2b outpatient clinical trial in migraine patients, Alexza must file a new IND with the DNP. It is projected that the Company will file this new IND in the fourth quarter of 2008 and initiate our Phase 2b outpatient study in the first quarter of 2009. AZ-104 has been licensed to Symphony Allegro, and Alexza has the right to repurchase all rights to this product candidate.

-- AZ-002 (Staccato alprazolam). Alexza is developing AZ-002 for the acute treatment of panic attacks associated with panic disorder. In June 2008, the Company announced the top line results of our in-clinic, single-center, double-blind, placebo-controlled, Phase 2a proof-of-concept clinical trial in patients with panic disorder. The primary aim of the clinical trial was to assess the safety and efficacy of a 1 mg single dose of AZ-002 in treating a pharmacologically-induced panic attack. Differences versus placebo in the intensity and the duration of a panic attack were collected at multiple time points during the study using psychological and physiological measurements. The study did not meet its two primary endpoints, which were the effect of AZ-002 on the incidence of a doxapram-induced panic attack and the effect of AZ-002 on the duration of a doxapram-induced panic attack, both as compared with placebo. There were no serious adverse events in the clinical trial, and AZ-002 was safe and well tolerated in the study patient population.

Thorough pharmacokinetic and pharmacodynamic analyses from this study show that alprazolam was administered in an IV-like manner with the Staccato system. Similar blood levels were observed in this study as were recorded during the AZ-002 Phase 1 PK and safety study in normal volunteers. Alexza and Symphony Allegro are completing work on the Phase 2a program for AZ-002 in acute panic attack. Following this com
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  Array BioPharma Inc. (NASDAQ: ... fourth quarter and full year of its fiscal ... Squarer, Chief Executive Officer of Array, noted, "Binimetinib and ... are on track for regulatory submissions in 2016. ... melanoma and BRAF-mutant colorectal cancer further validate the ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... ST. PAUL, Minn. , Aug. 3, 2015 /PRNewswire/ ... devices using neuroblocking therapy to treat obesity, metabolic diseases ... C. McDougal has been appointed to the Board ... serve as a Class II Director until the 2018 ... qualified. Ms. McDougal has served in an ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... of Novel Proteasome Inhibitor in ... Patients with Relapsed Solid Tumors, SOUTH SAN ... South Texas Accelerated Research Therapeutics (START),today announced the enrollment of ... Proteolix,s investigational drug, carfilzomib (PR-171).,START is participating in the study ...
... Protects the Ocular Surface Following Exposure to ... Dry Eye Symptoms, LAGUNA HILLS, Calif., Oct. 9 ... ALTY-0501, demonstrated statistically,significant advantages over vehicle in its ability ... Phase 2 study. The Phase 2 study utilized ...
Cached Medicine Technology:Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 2Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 3Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 2Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 3
(Date:8/3/2015)... Salt Lake City, UT (PRWEB) , ... August 03, 2015 , ... ... announced the release of the T500 cable , a Bluetooth Code Reader accessory ... mobile devices, including iOS products. The T500 helps enable a variety of barcode ...
(Date:8/3/2015)... , ... August 03, 2015 , ... According to an opinion piece published ... person’s diet leads to one pound of weight loss may not be accurate. While this ... translates to one pound of fat varies – based both on the individual and at ...
(Date:8/3/2015)... Los Angeles, California (PRWEB) , ... August 03, ... ... the Fifth Circuit Court of Appeals ruled in favor of the firm’s client ... Act ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
Breaking Medicine News(10 mins):Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Maik Behrens, Susann Foerster, Frauke Staehler, Jan-Dirk Raguse, and ... taste receptors are there to protect us from toxins, ... been debated whether we can discriminate between bitter-tasting compounds ... taste is encoded by a family of 25 TAS2 ...
... 13 AMERIGROUP,Corporation (NYSE: AGP ) today announced ... Investor Conference on November 27 in New,York City. ... Tuesday,November 27 at 2:00 p.m. Eastern Time, can be ... investors, page. A replay will be,available for 30 days, ...
... and Funds to Fight Homelessness in Los Angeles ... ANGELES, Nov. 13 United Way of Greater Los ... fight homelessness on,Saturday morning, November 17, 2007, by participating ... Park near downtown Los Angeles.,HomeWalk will engage participants through ...
... has chosen Rita B. Effros of the University of California, ... Kleemeier Award. This distinction is given annually to a GSA ... gerontology. , The award presentation will take place at GSA,s ... 16th - 20th, 2007 in San Francisco, CA. The actual ...
... Society of America (GSA) has chosen Lynn M. Martire ... of the Margret M. & Paul B. Baltes Foundation ... career contributions in behavioral and social gerontology. , The ... Scientific Meeting, which will be held from November 16th ...
... Nov. 13 Green Earth Waterless Carwash, the,only Los ... products and auto detailing services, today announced an agreement,with ... month as part of,the hospital,s employee appreciation program. An ... to the hospital. "We originally signed on for ...
Cached Medicine News:Health News:News Tips from the Journal of Neuroscience 2Health News:News Tips from the Journal of Neuroscience 3Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 3Health News:Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 2
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
... Family offers fast temperature control, exact block ... Personal cards enable safe program storage as ... individual protocols between different Mastercyclers. All models ... come with a two-year warranty. The ...
... 96 well thermocycler with ... Peltier technology for fastest available ... to 4C/sec with High Pressure ... PCR plates. Includes motorized ...
... graphical touch screen display which enables you ... of a screen." Features & Benefits ... Graphical Display, Memory Cards, Gradient Calculator, Fold ... Programmin, Free Instrument Software Upgrade. Includes ...
Medicine Products: